X

Drug Profile

DS 1211

Alternative Names: DS-1211

Latest Information Update: 26 Jun 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Daiichi Sankyo Company; Sanford Burnham Prebys Medical Discovery Institute
Class Small molecules
Mechanism of Action Alkaline phosphatase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Pseudoxanthoma elasticum
New Molecular Entity Yes

Highest Development Phases

Phase II Pseudoxanthoma elasticum

Most Recent Events

15 Nov 2023 Daiichi Sankyo completes a phase II trial in Pseudoxanthoma elasticum in Netherlands and USA (PO) (EudraCT2022-000676-19) (NCT05569252)
11 Nov 2022 Daiichi Sankyo plans a phase-II trial in Pseudoxanthoma elasticum in the US (Daiichi Sankyo pipeline, November 2022)
20 Oct 2022 Phase-II clinical trials in Pseudoxanthoma elasticum in USA (PO) (NCT05569252)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com